Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vital capacity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    655 result(s) found for: Vital capacity. Displaying page 1 of 33.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-000418-20 Sponsor Protocol Number: D1450C00001 Start Date*: 2006-04-06
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate...
    Medical condition: Moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended) NO (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003676-31 Sponsor Protocol Number: ROCK-ALS Start Date*: 2019-12-31
    Sponsor Name:Georg-August-Universität Göttingen
    Full Title: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
    Medical condition: Amyotrophic lateral sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001868-19 Sponsor Protocol Number: 2015-001 Start Date*: 2015-10-15
    Sponsor Name:University medical center of Johannes Gutenberg University Mainz
    Full Title: A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001163-24 Sponsor Protocol Number: GB28547 Start Date*: 2013-11-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.
    Medical condition: IDIOPATHIC PULMONARY FIBROSIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) GB (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004148-31 Sponsor Protocol Number: PREDMETH_NL71782.078.19 Start Date*: 2020-02-26
    Sponsor Name:Erasmus Medisch Centrum Dept. of Pulmonology
    Full Title: The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
    Medical condition: pulmonary sarcoidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003893-46 Sponsor Protocol Number: NA Start Date*: 2009-11-03
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: AZITHROMYCIN IN BRONCHIOLITIS OBLITERANS SYNDROME
    Medical condition: - Chronic rejection at 1 and 2 year post-lung transplantation - Mortality at 1 and 2 year post-lung transplantation - Acute rejection rate at 1 and 2 post-lung transplantation - Infection rate at 1...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029888 Obliterative bronchiolitis LLT
    12.0 10049202 Bronchiolitis obliterans LLT
    12.0 10068805 Follicular bronchiolitis LLT
    12.0 10019319 Heart-lung transplant rejection LLT
    12.0 10025127 Lung transplant LLT
    12.0 10050433 Prophylaxis against lung transplant rejection LLT
    12.0 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.0 10051604 Lung transplant rejection LLT
    12.0 10056409 Heart and lung transplant LLT
    12.0 10016547 FEV LLT
    12.0 10016549 FEV 1 abnormal LLT
    12.0 10016550 FEV 1 decreased LLT
    12.0 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021983-14 Sponsor Protocol Number: MLK002 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to treat BOS.
    Medical condition: -Mortality at 1 and 2 year post diagnosis of BOS -Infection rate during BOS -Evolution of pulmonary function after diagnosis of BOS
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022027-30 Sponsor Protocol Number: VIT001 Start Date*: 2010-09-23
    Sponsor Name:UZ Gasthuisberg
    Full Title: A randomized placebo-controlled double blind study to prevent BOS
    Medical condition: A study to prevent the occurence of chronic rejection after lung transplantation. Other points of investigation include lung function evolution, rate of survival, BAL cellularity, infection rate, r...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10068805 Follicular bronchiolitis LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10025127 Lung transplant LLT
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001152-35 Sponsor Protocol Number: UX003-CL201 Start Date*: 2013-08-02
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7
    Medical condition: Mucopolysaccharidosis type 7 (MPS 7, Sly syndrome)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002094-36 Sponsor Protocol Number: D3250C00038 Start Date*: 2016-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, U...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001713-20 Sponsor Protocol Number: ASTHMAFAST Start Date*: Information not available in EudraCT
    Sponsor Name:Centre Hospitalier Intercommunal de Créteil
    Full Title: Comparison of the efficacy and safety of budesonide/formoterol Turbuhaler® versus terbutaline nebulization as reliever therapy in children with asthma presenting at the emergency room for moderate ...
    Medical condition: moderate asthma exacerbation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10049585 Infantile asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064823 Asthmatic crisis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001160-29 Sponsor Protocol Number: NAL-II-19-1 Start Date*: 2019-06-24
    Sponsor Name:LABORATOIRES SMB S.A
    Full Title: A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001983-39 Sponsor Protocol Number: PHALS Start Date*: 2017-09-28
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled double blind randomized trial to investigate the efficacy and safety of the combination of Penicillin G / Hydrocortisone treatment in ALS patients (PHALS).
    Medical condition: Patients suffereing from Amytrophic Lateral Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002174-22 Sponsor Protocol Number: Avifibro Start Date*: 2006-11-08
    Sponsor Name:Mondobiotech Laboratories Anstalt
    Full Title: Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis
    Medical condition: Pulmonary Fibrosis categorized as UIP or NSIP
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000381-11 Sponsor Protocol Number: CCMK389X2201 Start Date*: 2020-06-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sar...
    Medical condition: Chronic pulmonary sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003158-18 Sponsor Protocol Number: 203PF203 Start Date*: 2018-09-12
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis
    Medical condition: mild to moderate Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) GR (Completed) BE (Completed) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005156-26 Sponsor Protocol Number: PRIN-SUGAR-2014 Start Date*: 2015-05-27
    Sponsor Name:Dr. Enrique Alday
    Full Title: Effects of neuromuscular block reversal with sugammadex vs neostigmine on postoperative respiratory outcomes after major abdominal surgery. A randomized controlled trial.
    Medical condition: Patients of both sexes proposed for major abdominal surgery under general anesthesia plus epidural
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000321-80 Sponsor Protocol Number: FGCL-3019-079 Start Date*: 2023-05-16
    Sponsor Name:FibroGen, Inc.
    Full Title: Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
    Medical condition: Duchenne Muscular Dystrophy
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2024-000461-24 Sponsor Protocol Number: LPS15677 Start Date*: 2024-12-18
    Sponsor Name:Genzyme
    Full Title: A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Late Onset Pompe Disease with One Year Alglucosidase Alfa Treatment
    Medical condition: Pompe's disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004088-77 Sponsor Protocol Number: BA2006/03/03 Start Date*: 2007-12-03
    Sponsor Name:BioAlliance Pharma
    Full Title: Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.
    Medical condition: Advanced hepatocarcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 21:43:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA